RESEARCH · RETATRUTIDE · PRECLINICAL AND LABORATORY MODELS
Retatrutide in Preclinical Research: Receptor Pharmacology, Obesity and Liver Models, Tumour Studies and Human Atrial Tissue
PurixLab’s Retatrutide 10mg is a research vial of LY3437943, a single peptide that activates three receptors: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Our earlier articles cover the clinical trial programme, glucagon receptor and energy expenditure and pharmacokinetics. This article stays in the laboratory: what cell, tissue and animal studies have reported, and where those models stop being informative. These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Receptor pharmacology and structure
In the discovery paper, LY3437943 showed balanced GCGR and GLP-1R activity in vitro but more GIPR activity. In obese mice it lowered body weight and improved glycaemic control, and the authors attributed part of the weight loss to GCGR-mediated increases in energy expenditure added to GIPR- and GLP-1R-driven reductions in calorie intake [1]. A 2024 structural study then examined how one peptide achieves triple agonism at GLP-1R, GIPR and GCGR [2]. For laboratory work this is the starting point: any readout in cells or tissue can reflect one, two or all three receptors, and attributing an effect to a single receptor requires selective antagonists or knockout systems.
Obesity models
- Diet-induced obese mice and hamsters. In mice, retatrutide reduced body weight by 31% (p < 0.0001 vs. vehicle), with loss of both fat and lean mass and lower food and water intake in the first days; energy expenditure was not significantly altered. In hamsters it shifted food preference toward chow and away from a high fat/cholesterol diet, and lean mass was not different after 5 weeks, with no change in bone mineral density [3].
- MC4R knockout mice. In a genetic model lacking the POMC-MC4R pathway, 21 days of treatment reduced body weight by 19.7 ± 4.1% with semaglutide, 31.6 ± 7.6% with tirzepatide and 24.1 ± 5.8% with retatrutide. All three suppressed fat and lean mass, improved insulin, HOMA-IR, cholesterol and AST/ALT, and reduced energy expenditure [4]. In this model retatrutide did not outperform tirzepatide.
- Combination with an amylin agonist. In diet-induced obese male rats, retatrutide combined with cagrilintide lowered body weight and food intake more than either agent alone or comparator combinations with semaglutide or tirzepatide. Pair-feeding showed the extra weight loss was not explained by reduced food intake alone [5].
The differences between these results, from a 31% reduction in one model to no clear advantage over tirzepatide in another, show how strongly the outcome depends on species, genetic background and comparator.
Liver and adipose tissue
Liver fat is a common readout. In the hamster model above, retatrutide did not reduce histopathological scoring, yet hepatic triglyceride content fell by 50% (p < 0.01) [3]. In a 31-day mouse model built from a Western diet, fructose and sucrose drinking water and a final fructose binge, retatrutide over the last 2 weeks reduced body weight, ALT, hepatic triglycerides, cholesterol and inflammatory markers in female mice. The same study found that females developed more severe liver injury after a single fructose binge than males, a reminder that sex is a variable in these models [6].
In high-fat-diet obese mice, multi-omic profiling of epididymal white fat after retatrutide showed suppressed lipogenesis, more fatty acid oxidation and mitochondrial function, and downregulated inflammatory and fibrotic pathways [7]. Because body weight fell at the same time, separating a direct tissue effect from the consequences of weight loss is difficult without weight-matched controls, a design used in the rat combination study [5].
Tumour models
Two groups have used retatrutide in obesity-linked cancer models. In mice with retatrutide-induced weight loss, pancreatic tumour volume was reduced 14-fold compared with a 4-fold reduction under semaglutide, and in a lung cancer model tumour engraftment was reduced by 50%; the benefits persisted after withdrawal despite weight regain [8]. In obese mouse models of triple-negative breast cancer, retatrutide lowered hexosamine pathway activity and YAP protein levels and reduced tumour size [9]. Both are mouse studies in which obesity itself drives tumour growth, so the results do not show a direct anti-tumour action of the peptide.
Brain, behaviour and heart tissue
- Diabetic rats. In streptozotocin-diabetic male rats, retatrutide lowered blood glucose but did not prevent diabetes-associated weight loss. Effects on memory were partial and task-dependent, with lower hippocampal TNF-α; the authors note that direct central exposure was not established [10].
- Alcohol discrimination. In an operant drug discrimination study in male and female rats, acute semaglutide, tirzepatide and retatrutide each attenuated alcohol discrimination, suggesting altered subjective effects of alcohol [11].
- Human atrial tissue. In right atrial preparations from heart surgery patients, retatrutide from 10 nM up to 100 nM raised force of contraction in a concentration- and time-dependent manner. The effect was diminished by GLP-1R, GIPR and GCGR antagonists but not by propranolol, and was linked to the cAMP system [12]. This is relevant context for the heart rate increases reported in the phase 2 obesity trial [13], though isolated atrial tissue cannot tell us what happens in an intact circulation.
What remains open
- Which receptor drives which effect in each tissue; few studies use receptor-selective tools.
- How much of each organ-level finding is a weight-loss effect rather than a direct one.
- Whether rodent findings in tumour, brain and behaviour models translate to any human setting.
- How peptide handling, vehicle and sex differences affect reproducibility across laboratories.
Retatrutide 10mg at PurixLab
Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/retatrutide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013
- Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 2024;10(1):77. PubMed 39019866 · PMC11255275 · doi:10.1038/s41421-024-00700-0
- Briand F, Le Cudennec C, Grasset E, et al. Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Obesity (Silver Spring). 2026;34 Suppl 1(Suppl 1):43-53. PubMed 41741376 · PMC13250738 · doi:10.1002/oby.70155
- Hitaka K, Sugawara T, Matsumoto M, et al. Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. Int J Obes (Lond). 2026;50(4):928-937. PubMed 41723268 · PMC13056526 · doi:10.1038/s41366-026-02025-2
- Petersen J, Merrild C, Holm SK, et al. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nat Metab. 2026;8(10):2069-2083. PubMed 42744908 · doi:10.1038/s42255-026-01603-y
- Viebahn GK, Khurana A, Freund L, et al. Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge. Am J Physiol Gastrointest Liver Physiol. 2025;329(6):G680-G695. PubMed 41056349 · PMC12643026 · doi:10.1152/ajpgi.00164.2025
- Li Q, Cheng W, Zhang J, et al. Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair. Diabetol Metab Syndr. 2026;18(1):120. PubMed 41964043 · PMC13214175 · doi:10.1186/s13098-026-02116-0
- Marathe SJ, Grey EW, Bohm MS, et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. NPJ Metab Health Dis. 2025;3(1):10. PubMed 40094000 · PMC11908972 · doi:10.1038/s44324-025-00054-5
- Cui X, Zhu Y, Zeng L, et al. Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP. Adv Sci (Weinh). 2025;12(11):e2407494. PubMed 39868848 · PMC11923992 · doi:10.1002/advs.202407494
- Keskin U, Altın E, Kara MK, et al. Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. Behav Brain Res. 2026;514:116343. PubMed 42385950 · doi:10.1016/j.bbr.2026.116343
- Windram M, Lovelock DF, Carew JM, et al. Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats. Psychopharmacology (Berl). 2026;243(5):1185-1197. PubMed 40699363 · PMC13242451 · doi:10.1007/s00213-025-06854-3
- Neumann J, Ahlrep U, Hofmann B, et al. Inotropic effects of retatrutide in isolated human atrial preparations. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(1):317-327. PubMed 40613938 · PMC12894140 · doi:10.1007/s00210-025-04421-3
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed 37366315 · doi:10.1056/NEJMoa2301972